Skip to main content

Drug Interactions between Addyi and mavorixafor

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

flibanserin mavorixafor

Applies to: Addyi (flibanserin) and mavorixafor

Flibanserin may increase the blood levels of mavorixafor. This may increase your risk of experiencing a change in the electrical activity of your heart called QT prolongation, which can result in irregular heartbeats that can be life-threatening. You might be more susceptible to this risk if you have heart problems, congenital long QT syndrome, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Your healthcare provider may be able to manage this risk with a dose adjustment or additional monitoring. You should seek immediate medical attention if you experience an irregular heartbeat or feel dizzy, lightheaded, or faint during treatment. Speak with your doctor or healthcare provider if you have any questions. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Drug and food interactions

Major

flibanserin food

Applies to: Addyi (flibanserin)

Do not use alcohol too close to the dosing time of flibanserin. Doing so can cause excessive drowsiness and decreases in blood pressure, which may lead to dizziness, lightheadedness, fainting, and accidental injury. Take flibanserin at bedtime to minimize the risk of these effects. It is recommended that you stop drinking alcohol at least two hours before taking flibanserin; otherwise, you should just skip the flibanserin dose that evening. Alcohol should not be consumed until at least the morning after taking flibanserin at bedtime. Because grapefruit juice can significantly increase the blood levels of flibanserin, you should also avoid the consumption of grapefruit and grapefruit juice during treatment. Talk to your healthcare provider if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Major

mavorixafor food

Applies to: mavorixafor

Mavorixafor should be taken on an empty stomach after an overnight fast, 30 minutes before food. Do not consume grapefruit products during treatment with mavorixafor unless otherwise directed by your doctor. Grapefruit juice can increase the blood levels and adverse effects of mavorixafor, increasing the risk of experiencing a change in the electrical activity of your heart called QT prolongation, which can result in irregular heartbeats that can be life-threatening. You should seek immediate medical attention if you experience an irregular heartbeat or feel dizzy, lightheaded, or faint during treatment. Speak with your doctor or healthcare provider if you have any questions. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.